Statera BioPharma Inc (STAB)

[lk52q]

Developing a therapy or drug treatment is a lengthy process that requires approval from federal authorities before it is profitable. In the meantime the company must devote its funding to research and development. But once approved, the payoff can be significant! $STAB

The research is based on the discovery that STAT-200, which originally was designed to antagonize opioid receptors, modulates multiple signaling pathways through receptors known as TLRs. These receptors act as master controllers of inflammation. Statera’s discovery platform identifies novel compositions that build upon STAT-200 by modulating multiple cellular targets, versus one, to restore cellular homeostasis. These findings have led to the selection of promising new compositions with the potential to treat a range of inflammatory-related diseases.